Prosecution Insights
Last updated: August 13, 2026
Application No. 18/238,773

SYSTEM AND METHODS FOR HARVESTING AND PROCESSING PERIOSTEUM FIBERS

Final Rejection §112
Filed
Aug 28, 2023
Priority
Sep 17, 2018 — provisional 62/732,210 +1 more
Examiner
SPENCE, JENNIFER SUZANNE
Art Unit
1633
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Allosource
OA Round
4 (Final)
66%
Grant Probability
Favorable
5-6
OA Rounds
8m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
82 granted / 124 resolved
+6.1% vs TC avg
Strong +51% interview lift
Without
With
+50.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
42 currently pending
Career history
172
Total Applications
across all art units

Statute-Specific Performance

§101
5.0%
-35.0% vs TC avg
§103
44.0%
+4.0% vs TC avg
§102
15.9%
-24.1% vs TC avg
§112
24.6%
-15.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 124 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-9 and 21-27, of record 2/12/2026, are pending and subject to prosecution. Claims 1 and 23 are amended. Status of Prior Rejections/Response to Arguments RE: Rejection of claims 1-9 and 21-27 are rejected under 35 U.S.C. 112(a): The applicant asserts that the composition of the plurality of individual periosteum fibers of amended claim 1 is inherently provided in an unstressed state with greater compressive elasticity versus periosteum fibers in bone-anchored periosteum or a plurality of fused periosteum fibers (Applicant Remarks, page 9-10). The applicant’s argument has been considered but is not found wholly persuasive. According to MPEP 2163.07(a), by disclosing in a patent application a device that inherently has a property, a patent application necessarily discloses that function, even though it says nothing explicit concerning it. The applicant argues that periosteal fibers, in the context of periosteum attached to bone or fused periosteal fibers, are intrinsically stressed and therefore possess less compressive elasticity than isolated fibers. The instant specification does not address or define the limitation “compressive elasticity”. The broadest reasonable interpretation is therefore considered to be the compressive modulus of elasticity, the ability of a material to resist deformation under compressive load (See Liu et al., Introduction). McBride et al. establish that fibers in intact periosteum experience higher axial strain (along the long axis of the bone) versus circumferential strain and that periosteal tissue exhibits shrinkage following isolation from bone largely in the axial direction (See page 1956, col. 2, full ¶1-2 and page 1957, col. 2, full ¶2), which supports the existence of anisotropic mechanical properties in periosteum. McBride et al. conducted their experiments by stretching the tissue samples (See page 1955, col. 2, full ¶3). It is noted that McBride et al. do not assess, or opine on, the compressive elasticity of periosteum, and no data on this functional aspect have been disclosed in the instant application. A greater compressive elasticity cannot therefore be considered an inherent property of individual periosteum fibers compared to periosteum fibers within bone-associated periosteum. Independent claim 1 also requires that the individual periosteum fibers provide the composition with greater compressive elasticity than fused periosteum fibers, however, no evidence of this property has been provided either. As such, the limitations directed toward compressive elasticity constitute new matter that is not supported by the disclosure. The rejection is maintained in modified form to address amended limitations. Maintained Rejections Claim Interpretation Claim 1 has been amended to require “greater compressive elasticity”. This limitation is not defined by the instant specification. The broadest reasonable interpretation is therefore considered to be a greater compressive modulus of elasticity, i.e., a greater ability of a material to resist deformation under compressive load (See Liu et al., Introduction). Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-9 and 21-27 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claims contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The new limitation of “greater compressive elasticity” in instant claims appears to represent new matter. MPEP 2163.06(I) notes, “If new matter is added to the claims, the examiner should reject the claims under 35 U.S.C. 112(a), pre-AIA first paragraph - written description requirement. In re Rasmussen, 650 F.2d 1212, 211 USPQ 323 (CCPA 1981).” The applicant has not identified any support for this limitation in the specification, and a review of the specification by the Examiner did not find any specific basis for the recited limitation. As noted by the MPEP, new matter includes not only the addition of wholly unsupported subject matter but may also include the introduction of claim changes which involve narrowing the claims by introducing elements or limitations which are not supported by the as-filed disclosure. Such introduction is a violation of the written description requirement of 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph. See, e.g., Fujikawa v. Wattanasin, 93 F.3d 1559, 1571, 39 USPQ2d 1895, 1905 (Fed. Cir. 1996). Specifically, the instant application does not provide any discrete information about the invention’s functional qualities. There is no characterization of the compressive elasticity of the invention, much less a comparison of its compressive elasticity to that of a matrix of periosteum fibers within a periosteum layer of bone or that of fused periosteum fibers shorter than a given size. Claim 1 defines the composition, in part, by means of a functional limitation, “greater compressive elasticity e”. However, the instant application lacks any data that explicitly demonstrate that the instant invention has greater compressive elasticity than periosteum or fused periosteum fibers or data that suggest or support a finding that the structure of the instant invention would likely have greater compressive elasticity. Such physical or structural data are required to support the functional limitation of claim 1 and establish that the applicant had possession of and/or fully envisaged the invention. In the absence of supporting evidence, the amended functional limitation represents new matter and is properly rejected as a written description deficiency under 35 U.S.C. 112(a). Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JENNIFER S SPENCE, whose telephone number is 571-272-8590. The examiner can normally be reached M-F 8:30-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Christopher M Babic, can be reached at 571-272-8507. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /J.S.S./Examiner, Art Unit 1633 /CHRISTOPHER M BABIC/Supervisory Patent Examiner, Art Unit 1633
Read full office action

Prosecution Timeline

Show 9 earlier events
Aug 12, 2025
Non-Final Rejection mailed — §112
Aug 12, 2025
Interview Requested
Aug 27, 2025
Applicant Interview (Telephonic)
Aug 27, 2025
Examiner Interview Summary
Feb 12, 2026
Response Filed
Apr 08, 2026
Final Rejection mailed — §112
Aug 10, 2026
Request for Continued Examination
Aug 11, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12685773
TREATMENT OF CD30-POSITIVE CANCER
3y 7m to grant Granted Jul 21, 2026
Patent 12685297
GENETICALLY MODIFIED MOUSE, METHODS FOR PRODUCING THE SAME, AND USES THEREOF
2y 6m to grant Granted Jul 21, 2026
Patent 12678493
COMPOSITIONS AND METHODS FOR MULTIPLEXED TUMOR VACCINATION WITH ENDOGENOUS GENE ACTIVATION
5y 9m to grant Granted Jul 14, 2026
Patent 12653842
Treatment Of Intervertebral Disc Degeneration
4y 8m to grant Granted Jun 16, 2026
Patent 12649932
ENHANCED VIRAL TRANSDUCTION OF MAMMALIAN CELLS USING MATERIAL SCAFFOLDS
3y 8m to grant Granted Jun 09, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
66%
Grant Probability
99%
With Interview (+50.7%)
3y 8m (~8m remaining)
Median Time to Grant
High
PTA Risk
Based on 124 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month